Neumora Therapeutics, Inc. Common Stock
Underestimation
| Parameter | Grade | Value | Sector average | Difference with sector, % | Average for 5 years | Difference from average, % |
|---|---|---|---|---|---|---|
| P/E |
0/10
|
0 | 48.77 | -100% | -8.33 | -100% |
| P/S |
|
0 | 33.76 | -100% |
|
|
| P/BV |
|
5.77 | 4.82 | 19.76% |
|
|
| P/FCF |
|
0 | 61 | -100% |
|
|
| Ev/Ebitda |
|
-12.47 | -22.15 | -43.68% |
|
|
| Ev/S |
|
0 | 22.56 | -100% |
|
|
| Ev/FCF |
|
-14.32 | 68.78 | -120.82% |
|
|
| E/P |
|
0 | 0.0178 | -100% |
|
|
Efficiency
| Parameter | Grade | Value | Sector average | Difference with sector, % | Average for 5 years | Difference from average, % |
|---|---|---|---|---|---|---|
| Ebitda margin |
0/10
|
0 | 4.98 | -100% | 0 | 0% |
| ROE |
|
-50.3 | 9.61 | -623.28% |
|
|
| ROA |
|
-47.55 | 0.3443 | -13911.34% |
|
|
| ROIC |
|
0 | 7.63 | -100% |
|
|
| ROS |
|
0 | -25.17 | -100% |
|
|
| ROCE |
|
-40.12 | 15.35 | -361.36% |
|
|
Debt
| Parameter | Grade | Value | Sector average | Difference with sector, % | Average for 5 years | Difference from average, % |
|---|---|---|---|---|---|---|
| Debt/Ebitda |
10/10
|
-0.0279 | -3.68 | -99.24% | -0.0297 | -5.95% |
| Nеt Debt/Ebitda |
|
1.97 | -3.44 | -157.23% |
|
|
| Debt/Ratio |
|
0.0105 | 0.1985 | -94.69% |
|
|
| Debt/Equity |
|
0 | 1.66 | -100% |
|
|
| Debt/Net Income |
|
-0.0222 | 10.32 | -100.21% |
|
|
Dividends
| Parameter | Grade | Value | Sector average | Difference with sector, % | Average for 5 years | Difference from average, % |
|---|---|---|---|---|---|---|
| Dividend yield |
0/10
|
0 | 0.5468 | -100% | 0 | 0% |
| Number of years of dividend growth |
|
0 | 0.2632 | -100% | ||
| DSI |
|
0 | 0.2193 | -100% |
|
|
| Average dividend growth |
|
0 | 0.4414 | -100% |
|
|
| Average percentage for 5 years |
|
0 | 0.4968 | -100% |
|
|
| Average percentage for payments |
|
0 | 43.56 | -100% |
|
|
| Difference from average difference in sector |
|
-0.5468 |
Growth impulse
| Parameter | Grade | Value | Sector average | Difference with sector, % | ||
|---|---|---|---|---|---|---|
| Growth impulse Revenue in 5 years |
0/10
|
0 | -56.89 | -100% | ||
| Growth impulse Ebitda in 5 years |
|
96.57 | -54.68 | -276.61% | ||
| Growth impulse Net Income in 5 years |
|
93521.03 | -58.33 | -160430.93% | ||
| Growth impulse FCF in 5 years |
|
481.48 | -49.48 | -1073.08% | ||
| Growth impulse EPS in 5 years |
|
127.36 | -32.41 | -492.97% |
IP Score
3.89/10
